Revive Therapeutics (TSE:RVV) has released an update.
Revive Therapeutics advances potential long COVID treatment with FDA meeting request for Bucillamine clinical study. The company’s research suggests the drug, previously studied for mild to moderate COVID-19, may improve oxygen levels in patients and inhibit the virus. Revive Therapeutics is also exploring Bucillamine for other rare disorders and infectious diseases.
For further insights into TSE:RVV stock, check out TipRanks’ Stock Analysis page.
